Dupilumab appears to have high effectiveness as well as safety in treating adult-onset atopic dermatitis (AD). This research represents the first study to evaluate this patient group specifically.

• In this retrospective case series, 16 patients (6 female and 10 male; median age 41 years; median age of the disease onset was 37.5 years; median span of the disease was 90 months) with the diagnosis of adult-onset AD, using dupilumab at standard dose for at least 3 months were analyzed.

• Median duration of the dupilumab therapy was 10.5 months, and mean percent decrease from baseline in eczema area severity index score was 85.8 ± 12.2 at 3 months, 90.7 ± 9.3 at 6 months, and 93.1 ± 5 at 12 months.

• Compared with the baseline, mean percent reduction in visual analog scale itch score was 82.2 ± 8.6 at 3 months.

• One patient receiving dupilumab developed acute vestibular neuritis, which resolved with anti-inflammatory therapy.